BIRC5 and neoplasm: Based on our evidence showing that survivin was significantly upregulated in the refractory MCL tumor cells and closely associated with cell proliferation property, we next determined the anti-tumor effects of survivin inhibition in MCL cell lines using the clinically tested survivin inhibitor YM155.